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portant to highlight and clarify the published harmonised definition [3].
1. Background
Newborn bloodspot screening for CF results in the recognition of a
small number of infantswith a positive screening result but an inconclu-
sive diagnosis, irrespective of the screening protocol used. TheNewborn bloodspot screening (NBS) for cystic fibrosis (CF) is a
successful public health strategy with a considerable impact on the
well-being of young people with CF [1]. Most infants with a positive
NBS result for CF will have either a clear diagnosis of CF (true positive
NBS result) or CF excluded (false positive NBS result), however a small
but significant number will have an inconclusive diagnosis. This is a
challenging situation for families and for healthcare professionals [2].
There has been progress over the past ten years with respect to the
evaluation, designation and management of these infants. This includes
a global harmonisation process undertaken in 2016, with a publication
in 2017, which provided a consistent international approach and defini-
tion [3,4]. A recent survey undertaken by the European CF Society
(ECFS) with support from the Cystic Fibrosis Foundation (CFF) NBS
Quality Improvement Group revealed significant confusionwith respect
to the designation of infants with inconclusive results after a positive
NBS test (Online appendix for summary). The survey, whichwill be pre-
sented at the 2019 European CF Conference, demonstrated that doctors
who classified themselves as CF specialists were as likely to be wrong
with diagnostic options as those who classified themselves asHey Children's Hospital, Eaton
European Cystic Fibrosis Society.
rben, S. Gartner, et al., Inconcl
is, https://doi.org/10.1016/j.jcrespiratory pediatric consultants. In light of these results, we felt it im-
proportion of inconclusive diagnosis increases when NBS protocols
use larger DNA panels and extended gene sequencing to identify cystic
fibrosis transmembrane conductance regulator (CFTR) gene variants [5].
A number of bodies have considered the evaluation andmanagement of
infants with these findings. An expert group convened by the CFF pro-
duced the diagnostic designation CFTR-related metabolic syndrome
(CRMS) to describe these infants [6]. This term is consistent with the
World Health Organisation International Disease Classification system
(aligned with CF) and is a designation that enables access to insurance
funds for healthcare in the US. In Europe, a panel of experts embarked
on aDelphi consensus exercise to determine guidance on the evaluation
of infants in this situation [7]. At this time, the consensus group did not
provide a designation for these infants as it was considered that a
“name” might increase the risk of over medicalisation. A subsequent
ECFS consensus determined agreement that a designation would be
useful and, after wide stakeholder engagement, the term CF Screen Pos-
itive, Inconclusive Diagnosis (CFSPID) was adopted [8].
2. Global harmonisation exercise
Therewas cross Atlantic acknowledgement that having two terms to
describe these infants was unsatisfactory and at a large international
meeting supported by the CFF, there was consensus that the terms
should be amalgamated to a joint CRMS/CFSPID designation with a
consistent definition (Fig. 1) [3]. The harmonised definition reflected
the increased capacity of the cftr2 website (https://www.cftr2.org/) tousive diagnosis after a positive newborn bloodspot screening result for
f.2019.04.010
Harmonised definition for Cystic Fibrosis Transmembrane Conductance Regulator- Related 
Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) 
definition 
The designation CRMS/CFSPID should be applied to an infant with;  
A positive NBS result for CF 
AND EITHER 
A sweat chloride value < 30 mmol/L and 2 CFTR variants* (mutations), at least one of 
which has unclear phenotypic consequences 
OR 
An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF causing variants**
(mutations) 
*the term “variant” is now preferred to “mutation”, which was used in original paper. (3)
**Information on CFTR variant characterisation can be accessed at https://www.cftr2.org/
Fig. 1. Harmonised definition for Cystic Fibrosis Transmembrane Conductance Regulator- Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis
(CFSPID) definition [3].
2 K.W. Southern et al. / Journal of Cystic Fibrosis xxx (2019) xxxcharacterise CFTR variants as “CF causing”, “non-CF causing”, “varying
clinical significance” or “unknown significance” [9]. The key difference
between previous definitions of CFSPID and CRMS and the new
harmonised definition was the inclusion of “CF causing variant” for
the infants with an intermediate sweat chloride (30–59 mmol/L). Con-
sequently an infant with two CFTR variants and an intermediate sweat
chloride will now be designated as CRMS/CFSPID if only one variant is
characterised as CF causing (Fig. 2). This is in contrast to the previous
ECFS definition of CFSPID, in which infants with two CFTR variants and
an intermediate sweat chloride would be referred for CF care.
3. What does this harmonised designation mean for healthcare
professionals?
There is guidance for the early evaluation of infants with an incon-
clusive diagnosis after a positive NBS result for CF [6,7]. Key pointsPositive newborn bloodspot s
Sweat chloride me 29 mmol/L 
30-59 mmo
No genetic analysis in





“CF not suspected” 
False positive NBS result
No CFTR variant 
detected through the
NBS protocol 
One or no CF caus
CRMS/CFS
Fig. 2. An algorithm for the designation of infants following a positive newborn bloodspot scr
(gene); CRMS, CFTR-related metabolic syndrome; CFSPID, CF screen positive, inconclusive diag
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cystic fibrosis; clar..., Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcinclude the organisation of a second sweat test to measure sweat chlo-
ride in a centre with a high level of experience. Infants with only one
CFTR variant recognised and a normal repeat sweat chloride
(b30 mmol/L) should be reported as carriers and no further testing un-
dertaken. Infants with a CRMS/CFSPID designation are well and have no
clinical features consistent with a diagnosis of CF. A positive outcome
from the consensus exercises has been a move away from over-
medicalising this situation and improved communication with families.
It is important, however, that these infants continue to have regular
clinical review by physicians with an interest in CF, as they have a risk
to develop significant clinical features consistent with CF.
4. What does this mean for families?
This is an extremely unsettling situation for families; the traditional
framework of health and disease is undermined [2]. Delivery of thecreening (NBS) result 
asurement 
l/L 
 60 mmol/L 
CF
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eening (NBS) result. (CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator
nosis; CRMS/CFSPID, harmonised definition)
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3K.W. Southern et al. / Journal of Cystic Fibrosis xxx (2019) xxxinitial positive NBS result and the subsequent inconclusive result places
the family in a psychologically vulnerable positionwith oscillating emo-
tions. It is essential that families have clear and precise information at all
stages of this process, including the longer term risks that a child with
CRMS/CFSPID faces, especially the development of a CFTR related disor-
der (CFTR-RD); a monosymptomatic clinical entity (for example,
CBAVD/pancreatitis/bronchiectasis) associated with CFTR dysfunction
that does not fulfill the diagnostic criteria for CF [3,10].
5. The outlook for these children
A number of infants with CRMS/CFSPIDwill develop clinical features
consistent with a diagnosis of CF, and will be transitioned to a CF diag-
nosis (albeit a less typical form in most cases). This is more likely to
occur for infants with an initial intermediate sweat chloride value [4].
In other CRMS/CFSPID infants, a diagnosis of CF may be established be-
cause of a subsequent positive sweat test result or from new knowledge
reclassifying a CFTR variant as CF causing (https://www.cftr2.org/
mutations_history). All infants with CRMS/CFSPID have a risk of devel-
oping a CFTR-RD, but the extent of this is not currently quantifiable
and likely relates to individual CFTR variants [11–14]. The accurate
designation of infants with CRMS/CFSPID is vital and facilitates the es-
tablishment of appropriate databases to monitor longterm outcomes.
This information will provide a clearer assessment of risk for children
with CRMS/CFSPID as they grow into adults.
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